Mindset and InterVivo Solutions Announce Availability of First Preclinical Psychedelic Benchmark Data from COPE Program
The COPE program, launched in March, aims to create the worlds first preclinical behavioral and pharmacokinetics benchmark data for clinically relevant psychedelic drugs including psilocybin, LSD, DMT, and 5-MeO-DMT, amongst others.
- The COPE program, launched in March, aims to create the worlds first preclinical behavioral and pharmacokinetics benchmark data for clinically relevant psychedelic drugs including psilocybin, LSD, DMT, and 5-MeO-DMT, amongst others.
- COPE data is available to InterVivo sponsors via a partnership between Mindset and InterVivo that will allow all parties to benefit from the use of COPE data.
- The COPE program data sets have been carefully built in partnership with InterVivos industry leading pre-clinical scientific team.
- For detailed information on the COPE Benchmark data set, please contact Sal Lemus, Director of Sales and Marketing at InterVivo.